Aktis Oncology
AbbVie and DISCO Pharmaceuticals Strike Strategic Collaboration on AND‑Gated Bispecific Therapeutics – Deal Worth Up to USD 2.5 Billion
DISCO Pharmaceuticals ("DISCO") announced a strategic collaboration and option‑to‑license agreement with AbbVie (NYSE: ABBV) to discover and develop novel AND‑gated bispecific therapeutics for solid tumors with high unmet medical need.…
Empowering Chinese Pharma’s Global Expansion
Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
